Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)

Schlüsselwörter

SARS-CoV-2-Infektionen - Chronisch-entzündliche Darmerkrankung - CED - Morbus crohn - Colitis ulcerosa

Publikationsverlauf

Eingereicht: 11. Januar 2024

Angenommen: 26. Januar 2024

Artikel online veröffentlicht:
10. April 2024

• Literatur

• 1 RKI. Stellen Autoimmunerkrankungen oder chronisch-entzündliche Erkrankungen Kontraindikationen gegen Impfungen dar?. 2020
• 2 Burisch J, Kiudelis G, Kupcinskas L. et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2018;
• 3 Burisch J, Katsanos KH, Christodoulou DK. et al. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis 2019; 13: 198-208
• 4 Sturm A, Atreya R, Bettenworth D. et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022; 60: 332-418
• 5 Kucharzik T, Dignass AU, Atreya R. et al. Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2019; 57: 162-241
• 6 Allocca M, Chaparro M, Gonzalez HA. et al. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med 2020; 9
• 7 Ardizzone S, Ferretti F, Monico MC. et al. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J Gastroenterol Hepatol 2021; 36: 3050-3055
• 8 Marafini I, Salvatori S, Sena G. et al. Low frequency of COVID-19 in inflammatory bowel diseases. Dig Liver Dis 2020; 52: 1234-1235
• 9 Norsa L, Cosimo P, Indriolo A. et al. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment. Gastroenterology 2020; 159: 2229-2231 e2
• 10 Rizzello F, Calabrese C, Salice M. et al. COVID-19 in IBD: The experience of a single tertiary IBD center. Dig Liver Dis 2021; 53: 271-276
• 11 Taxonera C, Sagastagoitia I, Alba C. et al. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2020; 52: 276-283
• 12 Wetwittayakhlang P, Albader F, Golovics PA. et al. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2021; 2021: 7591141
• 13 Amiot A, Rahier JF, Baert F. et al. The impact of COVID-19 on patients with IBD in a prospective European cohort study. J Crohns Colitis 2022;
• 14 Khan N, Patel D, Xie D. et al. Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans’ Affairs Cohort Study. Am J Gastroenterol 2021; 116: 808-810
• 15 Derikx L, Lantinga MA, de Jong DJ. et al. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. J Crohns Colitis 2021; 15: 529-539
• 16 Attauabi M, Poulsen A, Theede K. et al. Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study. J Crohns Colitis 2021; 15: 540-550
• 17 Singh AK, Jena A, Kumar MP. et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol J 2021; 9: 159-176
• 18 Koletzko L, Klucker E, Le Thi TG. et al. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J Clin Med 2021; 10
• 19 Burke KE, Kochar B, Allegretti JR. et al. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021; 27: 155-161
• 20 Gubatan J, Levitte S, Balabanis T. et al. SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California. Gastroenterology 2020; 159: 1141-1144 e2
• 21 Khan N, Mahmud N, Trivedi C. et al. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021; 70: 1657-1664
• 22 MacKenna B, Kennedy NA, Mehrkar A. et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol 2022; 4: e490-e506
• 23 Bezzio C, Saibeni S, Variola A. et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020; 69: 1213-1217
• 24 Brenner EJ, Ungaro RC, Gearry RB. et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020; 159: 481-491.e3
• 25 Hong SJ, Bhattacharya S, Aboubakr A. et al. COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study. Therap Adv Gastroenterol 2022; 15
• 26 Lin S, Lau LH, Chanchlani N. et al. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022; 71: 1426-1439
• 27 Teich N, Ludewig C, Schmelz R. et al. [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease]. Z Gastroenterol 2021; 59: 1189-1196
• 28 Ricciuto A, Lamb CA, Benchimol EI. et al. Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2022; 16: 591-600
• 29 Creemers RH, Rezazadeh Ardabili A, Jonkers DM. et al. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. PLoS One 2021; 16: e0258271
• 30 Hadi Y, Dulai PS, Kupec J. et al. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Aliment Pharmacol Ther 2022; 55: 191-200
• 31 Roy S, Sheikh SZ, Furey TS. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD. Sci Rep 2021; 11: 16522
• 32 Sperger J, Shah KS, Lu M. et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021; 11: e049740
• 33 Batsiou A, Mantzios P, Piovani D. et al. SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review. J Clin Med 2022; 11
• 34 Ungaro RC, Agrawal M, Park S. et al. Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. ACR Open Rheumatol 2021; 3: 111-115
• 35 Kjeldsen S, Nielsen J, Mertz Norgard B. et al. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2022; 28: 1513-1519
• 36 Tripathi K, Godoy Brewer G, Thu Nguyen M. et al. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2022; 28: 1265-1279
• 37 Ungaro RC, Brenner EJ, Gearry RB. et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70: 725-732
• 38 Ungaro RC, Brenner EJ, Agrawal M. et al. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology 2022; 162: 316-319 e5
• 39 Meyer A, Semenzato L, Zureik M. et al. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021; 54: 160-166
• 40 Maslennikov R, Ivashkin V, Vasilieva E. et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther 2021; 69: 102039
• 41 Brenner EJ, Pigneur B, Focht G. et al. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clin Gastroenterol Hepatol 2021; 19: 394-396.e5
• 42 Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020; 69: 1335-1342
• 43 RKI. Epidemiologisches Bulletin. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/21_23.pdf?__blob=publicationFile (Abruf am 25.06.2023) 2023;21/2023.
• 44 Giszas B, Trommer S, Schüßler N. et al. Post-COVID-19 condition is not only a question of persistent symptoms: structured screening including health-related quality of life reveals two separate clusters of post-COVID. Infection 2023; 51: 365-377
• 45 Salvatori S, Baldassarre F, Mossa M. et al. Long COVID in Inflammatory Bowel Diseases. J Clin Med 2021; 10
• 46 Khan N, Mahmud N, Patel M. et al. Incidence of Long COVID and Impact of Medications on the Risk of Developing Long COVID in a Nationwide Cohort of IBD Patients. Clin Gastroenterol Hepatol 2023; 21: 1960-1962.e1
• 47 DGPI. Ergebnisse des PIMS-Ssurveys (01.01.2020–30.04.2023). https://dgpi.de/pims-survey-update/ (Abruf am 25.06.2023) 2023.
• 48 Watanabe A, Kani R, Iwagami M. et al. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. JAMA Pediatr 2023; 177: 384-394
• 49 RKI. Allgemeine Infektionsschutzmassnahmen. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/nCoV_node.html#doc13490882bodyText5 (Abruf am 25.06.2023) 2023.
• 50 Occhipinti V, Pastorelli L. Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy. Inflamm Bowel Dis 2020; 26: 793-796
• 51 RKI Hygieneregeln Corona. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Hygiene.html
• 52 de Jong MJ, Boonen A, van der Meulen-de Jong AE. et al. Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clin Gastroenterol Hepatol 2020; 18: 1744-1752
• 53 de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ. et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017; 390: 959-968
• 54 Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis 2017; 23: 894-902
• 55 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 74-80
• 56 Kucharzik T, Wittig BM, Helwig U. et al. Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity. Clin Gastroenterol Hepatol 2017; 15: 535-542 e2
• 57 Maaser C, Petersen F, Helwig U. et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut 2020; 69: 1629-1636
• 58 Rimola J, Torres J, Kumar S. et al. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 2022; 71: 2587-2597
• 59 Johnston ER, Habib-Bein N, Dueker JM. et al. Risk of bacterial exposure to the endoscopist’s face during endoscopy. Gastrointest Endosc 2019; 89: 818-824
• 60 van Doremalen N, Bushmaker T, Morris DH. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564-1567
• 61 Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020; 158: 1518-1519
• 62 Xiao F, Tang M, Zheng X. et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020; 158: 1831-1833 e3
• 63 Song Y, Liu P, Shi XL. et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020; 69: 1143-1144
• 64 Wolfel R, Corman VM, Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465-469
• 65 Repici A, Pace F, Gabbiadini R. et al. Endoscopy Units and the Coronavirus Disease 2019 Outbreak: A Multicenter Experience From Italy. Gastroenterology 2020; 159: 363-366 e3
• 66 Repici A, Maselli R, Colombo M. et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. Gastrointest Endosc 2020; 92: 192-197
• 67 Jarchum I, Liu M, Shi C. et al. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun 2012; 80: 2989-2996
• 68 Chen X, Cui J, Yan Z. et al. Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system. Genes Dis 2015; 2: 96-105
• 69 Gralnek IM, Hassan C, Beilenhoff U. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy 2020; 52: 483-490
• 70 Sultan S, Lim JK, Altayar O. et al. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology 2020; 159: 739-758 e4
• 71 Sultan S, Siddique SM, Singh S. et al. AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. Gastroenterology 2021; 161: 1011-1029 e11
• 72 Chiu PWY, Ng SC, Inoue H. et al. Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements). Gut 2020; 69: 991-996
• 73 Hayee B, group Sp, East J. et al. Multicentre prospective study of COVID-19 transmission following outpatient GI endoscopy in the UK. Gut 2021; 70: 825-828
• 74 Repici A, Aragona G, Cengia G. et al. Low risk of COVID-19 transmission in GI endoscopy. Gut 2020; 69: 1925-1927
• 75 Vavricka SR, Tutuian R, Imhof A. et al. Air suctioning during colon biopsy forceps removal reduces bacterial air contamination in the endoscopy suite. Endoscopy 2010; 42: 736-741
• 76 Gralnek IM, Hassan C, Ebigbo A. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. Endoscopy 2022; 54: 211-216
• 77 Brenner EJUR, Colombel JF. et al. SECURE-IBD Database Public Data Update.. covidibd.org. 2022
• 78 Macaluso FS, Giuliano A, Fries W. et al. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. Inflamm Bowel Dis 2023; 29: 217-221
• 79 Taskforce. PDCAobotC-E. 2020. 2020 https://ecco-ibd.eu/images/6_Publication/6_8_Surveys/1st_interview_COVID-19%20ECCOTaskforce_published.pdf letzter Aufruf am 29.03.2020.
• 80 Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn’s Disease. J Crohns Colitis 2016; 10: 371-372
• 81 van Linschoten RCA, Jansen FM, Pauwels RWM. et al. Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol 2023; 8: 343-355
• 82 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473-475
• 83 Wu C, Chen X, Cai Y. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934-943
• 84 Gianfrancesco M, Hyrich KL, Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79: 859-866
• 85 Boteanu A, Leon L, Esteban SP. et al. Severe COVID-19 in patients with immune-mediated rheumatic diseases: a stratified analysis from the SORCOM multicenter registry. Mod Rheumatol 2023; 34: 97-105
• 86 Limen RY, Sedono R, Sugiarto A. et al. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 2022; 20: 425-434
• 87 Baker D, Forte E, Pryce G. et al. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination. Mult Scler Relat Disord 2023; 69: 104425
• 88 COVRIIN. COVID-19-Therapieempfehlungen: Interaktive Orientierungshilfe für Ärztinnen und Ärzte. 2023 http://www.dgiin.de/covriin/index.html#/
• 89 Classen JM, Muzalyova A, Nagl S. et al. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany. Dig Dis 2022; 40: 719-727
• 90 Dai C, Dong ZY, Wang YN. et al. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. Rev Esp Enferm Dig 2023; 115: 306-314
• 91 Ramos L, Hernandez-Porto M, Carrillo-Palau M. et al. Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis 2022;
• 92 Alexander JL, Kennedy NA, Ibraheim H. et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol 2022; 7: 342-352
• 93 Alexander JL, Liu Z, Munoz Sandoval D. et al. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol 2022; 7: 1005-1015
• 94 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A. et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology 2022; 162: 454-467
• 95 Macaluso FS, Principi M, Facciotti F. et al. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. Dig Liver Dis 2023; 55: 154-159
• 96 Shiga H, Kakuta Y, An K. et al. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. J Gastroenterol Hepatol 2023; 38: 44-51
• 97 Quan J, Ma C, Panaccione R. et al. Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol 2022; 7: 1077-1079
• 98 Li D, Debbas P, Mujukian A. et al. Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. Inflamm Bowel Dis 2023; 29: 883-887
• 99 Kwon HJ, Panagos K, Alizadeh M. et al. Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination. Front Med (Lausanne) 2022; 9: 1005121
• 100 Łodyga M, Maciejewska K, Rydzewska G. A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vaccination in 267 Patients with Inflammatory Bowel Disease in Poland. Med Sci Monit 2022; 28: e938665